Cell Line-Derived Xenograft Models

Predict the success of your novel cancer therapy with our cell line-derived xenograft models.

With our experts, choosing the cell line-derived xenograft (CDX) mouse model that best fits your pharmaceutical R&D is quick and simple. Leverage our extensive resources and deep knowledge of in vivo modeling to harness the full potential of our CDX mouse model range.

Expand your evaluation insights by complementing your chosen CDX mouse model with the corresponding syngeneic model for your preclinical testing. With our personalized study designs, together, we can push your cancer therapy through its early testing and on its way to the clinic.

Evaluate oncology therapies against human cells—early and reliably

CDX mouse models implanted with well-characterized cancer cell lines offer a consistent tumor phenotype and provide the early opportunity to assess your novel drugs against human cells.

With their ease of use and cost-effectiveness, CDX models are a reliable screening tool—ensuring that you invest in the most promising candidates.

Advantages of choosing a CDX mouse model

  • Assess with confidence: Get reliable, reproducible data when you work with a CDX model derived from established cancer cell lines.
  • Get species-specific evaluation data: Enhance your understanding of species-specific drug interactions with easy access to human cancer cells.
  • Streamline your preclinical testing: Screen new therapies using CDX mouse models and complementary syngeneic models for a seamless R&D experience.

Elevate your preclinical research with our validated CDX mouse models

Explore the potential of your novel therapeutic in any of our CDX mouse models to gain early insights into how your cancer drug behaves in its intended target species.

Take your cancer therapy further with custom studies

Let us facilitate your drug development with bespoke study designs made for you. Integrate any of our expert services and additional analyses, including

  • IVIS imaging
  • Whole blood, spleen, and lymph node analysis
  • Histology and IHC-IFC
  • PK studies
  • General observations
  • Metabolic analyses
  • Pain analysis

Don’t see what you’re looking for? Get in touch to discuss a custom solution.

Data Highlight: Chemotherapy validation with Paclitaxel and Cisplatin

Chemotherapy validation in human lung cancer A549 xenograft model. 5 x106 A549 cells were subcutaneously injected into the rear flank of nude mice. Once the tumor size reached ~100mm3 (Day19), mice were randomized into vehicle control group (treated with normal saline), paclitaxel (20 mg/kg, IP twice/week), and cisplatin group (3 mg/kg, IP twice/week). Tumor volume was monitored twice per week using calipers. Data are mean ± SEM; n=5 /group; ** P<0.01, *** P<0.001 by Student’s t-test.

Are CDX mouse models right for you?

Although CDX mice are useful for initial drug candidate screening and early validation studies, their simplicity is not suited to all pharmaceutical R&D applications. Our patient-derived xenograft (PDX) models are excellent at retaining the tumor heterogeneity of the patient’s original tumor, making them more representative of clinical scenarios and suitable for use in humanized mice to study tumor-immune system interactions.

To better evaluate your novel immunotherapies, explore our syngeneic tumor models and test the treatment response in an intact immune system. Our syngeneic mice provide the perfect solution for studying immune therapies such as CAR-T or checkpoint inhibitors. With complementary tumor types across our modeling options, we have something for every oncology R&D need.

Are you ready to push your oncology R&D forward with CDX models?